Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial

Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial

<p><strong>Objective</strong> To evaluate the cost-effectiveness of an inflammatory biomarker and clinical symptom directed tight control strategy (TC) compared with symptom-based clinical management (CM) in patients with Crohn’s disease (CD) naïve to immunosuppressants and biologi...

Full description

Bibliographic Details
Main Authors:	Panaccione, R, Colombel, J, Travis, S, Bossuyt, P, Baert, F, Vaňásek, T, Danalıoğlu, A, Novacek, G, Armuzzi, A, Reinisch, W, Johnson, S, Buessing, M, Neimark, E, Petersson, J, Lee, W, D'Haens, G
Format:	Journal article
Language:	English
Published:	BMJ Publishing Group 2019

Similar Items

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
by: Colombel, J, et al.
Published: (2017)

Biomarker correlation with endoscopic outcomes in patients with Crohn's disease: data from CALM
by: Reinisch, W, et al.
Published: (2018)

Lymphoma risk and overall safety profile of Adalimumab in patients with Crohn's disease with up to 6 years of follow-up in the pyramid
by: D'Haens, G, et al.
Published: (2018)

Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM
by: Yzet, C, et al.
Published: (2019)

The Crohn's disease–ulcerative colitis clinical appraisal update: emerging trends in clinical practice
by: Sandborn, W, et al.
Published: (2016)

Review: Efficacy and safety of adalimumab in Crohn's disease
by: Gary R. Lichtenstein, et al.
Published: (2008-07-01)

Development of red flags index for early referral of adults with symptoms and signs suggestive of Crohn’s disease: an IOIBD initiative
by: Danese, S, et al.
Published: (2015)

Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process.
by: Peyrin-Biroulet, L, et al.
Published: (2012)

Biologic Therapies: From Complexity to Clinical Practice in a Changing Environment
by: Remo Panaccione, et al.
Published: (2015-12-01)

Leukocytoclastic Vasculitis Associated with Adalimumab Therapy for Crohn’s Disease
by: Lankai Cathy Xu, et al.
Published: (2023-03-01)

CROHN'S DISEASE: GENERAL CHARACTERISTICS AND TREATMENT WITH ADALIMUMABE BIOPHARMACEUTICAL
by: S. A. Marques, et al.
Published: (2018-02-01)

Adalimumab for the treatment of Crohn&rsquo;s disease
by: Andrea Cassinotti, et al.
Published: (2008-09-01)

Letter: should immunosuppressive therapy be started with adalimumab in Crohn's disease? Authors' reply.
by: Reenaers, C, et al.
Published: (2013)

Tuberculous monoarthritis after treatment with adalimumab in Crohn's disease Monoartritis tuberculosa tras tratamiento con adalimumab en enfermedad de Crohn
by: Alejandro Martínez-Caselles, et al.
Published: (2012-03-01)

Characterization of Mucosal Lesions in Crohn's Disease Scored With Capsule Endoscopy: A Systematic Review
by: Miquel Marquès Camí, et al.
Published: (2021-01-01)

Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?
by: Reenaers, C, et al.
Published: (2012)

Adalimumab and azathioprine in the prevention of postoperative crohn’s disease recurrence
by: A. V. Poletova, et al.
Published: (2020-10-01)

Crohn’s Disease Associated Pyoderma Gangrenosum Treated with Adalimumab
by: Despoina Kakagia, et al.
Published: (2012-03-01)

Efficacy of adalimumab for Crohn’s disease in real clinical practice
by: O V Knyazev, et al.
Published: (2017-02-01)

European evidence based consensus on the diagnosis and management of Crohn's disease: current management.
by: Travis, S, et al.
Published: (2006)

Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: results from an international survey and discussion programme.
by: Ferrante, M, et al.
Published: (2012)

Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease.
by: D'Haens, G, et al.
Published: (2009)

Segundo consenso europeo basado en evidencia sobre el diagnóstico y manejo de la colitis ulcerosa crónica idiopática. Parte 2: tratamiento actual (versión española)
by: A. Dignass, et al.
Published: (2015-01-01)

Evolving concepts in Phase I and II Drug Development for Crohn's Disease.
by: Jairath, V, et al.
Published: (2016)

Listeria Monocytogenes Brain Abscess in Crohn’s Disease Treated with Adalimumab
by: Amporn Atsawarungruangkit, et al.
Published: (2017-11-01)

Difficult-to-treat-pediatric Crohn's disease: focus on adalimumab
by: Zeisler B, et al.
Published: (2015-04-01)

Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
by: Jong Pil Im
Published: (2017-04-01)

Review article: defining remission in ulcerative colitis.
by: Travis, S, et al.
Published: (2011)

Adalimumab induction therapy achieves clinical remission and response in Chinese patients with Crohn's disease
by: Wu, K, et al.
Published: (2015)

Update on the management of inflammatory bowel disease: specific role of adalimumab
by: Guidi L, et al.
Published: (2011-07-01)

Evolving concepts in phases I and II drug development for Crohn's Disease
by: Jairath, V, et al.
Published: (2016)

Adherence to and Persistence with Adalimumab Therapy among Swedish Patients with Crohn’s Disease
by: Yifei Liu, et al.
Published: (2022-07-01)

Distinct alterations of fecal microbiota refer to the efficacy of adalimumab in Crohn’s disease
by: Liang Chen, et al.
Published: (2022-08-01)

Isolated Bilateral Gastrocnemius Myositis in Crohn Disease Successfully Treated with Adalimumab
by: Salvatore Vadala di Prampero, et al.
Published: (2016-11-01)

Infliximab-graded challenge in a patient with Crohn’s disease and adalimumab hypersensitivity
by: Song Christine H, et al.
Published: (2012-11-01)

HEPATITIS AND PNEUMONITIS DURIN ADALIMUMAB THERAPY IN CROHN? DISEASE: mind the histoplasmosis!
by: Bruno do Valle PINHEIRO, et al.
Published: (2014-03-01)

Comparison between infliximab and adalimumab in the treatment of perianal fistulas in Crohn's disease
by: Carlos Henrique Marques dos Santos
Published: (2014-07-01)

Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease Eficacia del adalimumab en el tratamiento de las manifestaciones extraintestinales de la enfermedad de Crohn
by: Manuel Barreiro-de-Acosta, et al.
Published: (2012-09-01)

Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease
by: Wu, K, et al.
Published: (2016)

Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab
by: Armuzzi A, et al.
Published: (2013-04-01)